2 Incredibly Cheap Dividend Stocks to Buy Now
Dividend stocks are always a rock-solid choice as an investing vehicle. Companies that pay dividends are generally proven commodities in their respective fields, they typically have strong positive free cash flows, and these types of equities allow investors to take advantage of the power of compounding -- via dividend reinvestment plans -- to magnify returns over the long-term.
The one problem with dividend stocks is that most of these equities trade at sky-high premiums because of these built-in advantages over growth stocks. Because of the political turmoil over the drug pricing debate in the U.S., however, a handful of large cap pharmaceutical stocks are currently trading at extremely attractive valuations.
Which dividend-paying drug manufacturers are the best buys right now? Amgen (NASDAQ: AMGN) and Bristol Myers Squibb (NYSE: BMY) both sport dirt cheap valuations, healthy dividend yields, and intriguing growth prospects over the next 10 years. While both of these blue-chip pharma stocks have had an off year in terms of their share price performance in 2021, savvy investors might be wise to capitalize on this recent weakness. Here's a brief overview of the pros and cons associated with each of these top flight dividend-paying pharma stocks.
Source Fool.com
